CA3177377A1 - Compositions and methods for treating pulmonary edema or lung inflammation - Google Patents
Compositions and methods for treating pulmonary edema or lung inflammationInfo
- Publication number
- CA3177377A1 CA3177377A1 CA3177377A CA3177377A CA3177377A1 CA 3177377 A1 CA3177377 A1 CA 3177377A1 CA 3177377 A CA3177377 A CA 3177377A CA 3177377 A CA3177377 A CA 3177377A CA 3177377 A1 CA3177377 A1 CA 3177377A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- lung
- hours
- serum
- hyperoxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000939P | 2020-03-27 | 2020-03-27 | |
| US63/000,939 | 2020-03-27 | ||
| PCT/US2021/024345 WO2021195488A1 (en) | 2020-03-27 | 2021-03-26 | Compositions and methods for treating pulmonary edema or lung inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177377A1 true CA3177377A1 (en) | 2021-09-30 |
Family
ID=77892642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177377A Pending CA3177377A1 (en) | 2020-03-27 | 2021-03-26 | Compositions and methods for treating pulmonary edema or lung inflammation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12569459B2 (https=) |
| EP (1) | EP4126104A4 (https=) |
| JP (1) | JP2023520770A (https=) |
| CN (1) | CN115551569A (https=) |
| CA (1) | CA3177377A1 (https=) |
| MX (1) | MX2022011821A (https=) |
| WO (1) | WO2021195488A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025024778A1 (en) * | 2023-07-27 | 2025-01-30 | Regents Of The University Of Minnesota | Medical treatment system and methods |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716877B2 (en) | 2001-01-31 | 2004-04-06 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| CA2578709C (en) | 2004-06-17 | 2010-06-15 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| US9220788B2 (en) * | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| US8309080B2 (en) | 2007-12-06 | 2012-11-13 | Naidu Lp | Metallo-protein and tocotrienol (MP-T3) compositions and uses thereof |
| US8304401B2 (en) | 2008-09-02 | 2012-11-06 | Trustees Of Dartmouth College | Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels |
| WO2010124372A1 (en) * | 2009-04-29 | 2010-11-04 | Genomedx Biosciences, Inc. | Systems and methods for expression-based classification of thyroid tissue |
| PT2501413T (pt) | 2009-11-18 | 2019-07-10 | Nektar Therapeutics | Formas de sal de ácido de conjugados de polímero-fármaco |
| EP3119768B1 (en) | 2014-03-16 | 2019-07-31 | Hadasit Medical Research Services And Development Ltd. | 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer |
| US9913819B2 (en) | 2014-06-12 | 2018-03-13 | Yale University | Methods of treating or preventing fibrotic lung diseases |
| CN107041879A (zh) | 2017-04-01 | 2017-08-15 | 深圳市润佳通科技有限公司 | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用 |
| MX2020007971A (es) | 2018-01-31 | 2020-09-09 | Univ Minnesota | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. |
| WO2019178023A1 (en) | 2018-03-12 | 2019-09-19 | Yale University | Methods of Treating or Preventing Acute Respiratory Distress Syndrome |
-
2021
- 2021-03-26 EP EP21776008.1A patent/EP4126104A4/en active Pending
- 2021-03-26 US US17/914,942 patent/US12569459B2/en active Active
- 2021-03-26 CA CA3177377A patent/CA3177377A1/en active Pending
- 2021-03-26 JP JP2022558131A patent/JP2023520770A/ja active Pending
- 2021-03-26 WO PCT/US2021/024345 patent/WO2021195488A1/en not_active Ceased
- 2021-03-26 CN CN202180038002.8A patent/CN115551569A/zh active Pending
- 2021-03-26 MX MX2022011821A patent/MX2022011821A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023520770A (ja) | 2023-05-19 |
| EP4126104A4 (en) | 2024-04-17 |
| US20230147865A1 (en) | 2023-05-11 |
| MX2022011821A (es) | 2022-10-10 |
| EP4126104A1 (en) | 2023-02-08 |
| CN115551569A (zh) | 2022-12-30 |
| US12569459B2 (en) | 2026-03-10 |
| WO2021195488A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11883528B2 (en) | Compositions and methods for treating pulmonary edema or lung inflammation | |
| ES2399279T3 (es) | Formulaciones de tobramicina para el tratamiento de infecciones endobronquiales | |
| Alothman et al. | Bronchial constriction and inhaled colistin in cystic fibrosis | |
| US6702998B2 (en) | Methods and devices for treating lung dysfunction | |
| US20100330061A1 (en) | Methods and Devices for Treating Lung Dysfunction | |
| AU2002211222A1 (en) | Therapeutic use of aerosolized S-nitrosoglutathione in cystic fibrosis | |
| WO2002032418A1 (en) | Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis | |
| Vendrell et al. | Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis | |
| Wagener et al. | Anesthetic concerns in patients presenting with renal failure | |
| US20250082715A1 (en) | Compositions and methods for treatment of acute lung injury | |
| van ‘t Veen et al. | Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity | |
| US20220265775A1 (en) | Compositions and methods for treating pulmonary edema or lung inflammation | |
| US12569459B2 (en) | Compositions and methods for treating pulmonary edema or lung inflammation | |
| ES3009563T3 (en) | Genotype-agnostic rescue of cystic fibrosis with small molecule bicarbonate channels | |
| WO2015002818A1 (en) | Treating or preventing nephrogenic diabetes insipidus | |
| HK40087339A (zh) | 用於治疗肺水肿或肺炎的组合物和方法 | |
| HK40046684A (en) | Compositions and methods for treating pulmonary edema or lung inflammation | |
| Multz | Vasopressin dysregulation and hyponatremia in hospitalized patients | |
| Narasimhan et al. | New and investigational treatments in cystic fibrosis | |
| RU2817906C2 (ru) | Композиции и способы лечения острого повреждения легких | |
| Kappeler et al. | Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250321 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250321 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250321 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250324 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250516 |